Gabrielle Macaron

3 weeks ago | neurologylive.com | Gabrielle Macaron |Isabella Ciccone

WATCH TIME: 5 minutes"Younger age and short disease duration are both considered to be positive treatment effect modifiers in the sense that they are associated with better treatment response, specifically for a higher efficacy medication."A recent expert-led session, chaired by Scott D. Newsome, DO, MSCS, FAAN, FANA, addressed the increasingly complex landscape of disease-modifying therapy (DMT) selection in multiple sclerosis (MS).